Clinical trial
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes…
NCT00392353 · National Cancer Institute (NCI), NIH · Active, not recruiting
Key facts
| NCT number | NCT00392353 |
|---|---|
| Title | Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia |
| Official title | A Phase 1/2 Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination With Azacitidine in Patients With the Myelodysplastic Syndrome (MDS) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Active, not recruiting |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Acute Erythroid Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Ring Sideroblasts, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia |
| Intervention type | Drug, Other |
| Interventions | Azacitidine, Laboratory Biomarker Analysis, Pharmacological Study, Vorinostat |
| Enrollment | 135 |
| Start date | Nov 22, 2006 |
| Primary completion | Dec 31, 2026 |
| Completion | Dec 31, 2026 |
| First posted | Oct 26, 2006 |
| Last update posted | Feb 13, 2026 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: